Your browser doesn't support javascript.
Three Cases of COVID-19 Pneumonia That Responded to Icosapent Ethyl Supportive Treatment.
Suh, Winston; Urits, Ivan; Viswanath, Omar; Kaye, Alan D; Patel, Haresh; Hall, Wade; Eskander, Jonathan P.
  • Suh W; Department of Anesthesiology, Louisiana State University Health Shreveport, Shreveport, LA, USA.
  • Urits I; Department of Anesthesia, Critical Care, and Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • Viswanath O; Department of Anesthesiology, Louisiana State University Health Shreveport, Shreveport, LA, USA.
  • Kaye AD; University of Arizona College of Medicine-Phoenix, Phoenix, AZ, USA.
  • Patel H; Department of Anesthesiology, Creighton University School of Medicine, Omaha, NE, USA.
  • Hall W; Valley Anesthesiology and Pain Consultants-Envision Physician Services, Phoenix, AZ, USA.
  • Eskander JP; Department of Anesthesiology, Louisiana State University Health Shreveport, Shreveport, LA, USA.
Am J Case Rep ; 21: e928422, 2020 Dec 14.
Article in English | MEDLINE | ID: covidwho-976579
ABSTRACT
BACKGROUND Icosapent ethyl, a form of eicosapentaenoic acid with anti-inflammatory activity, has been approved as an adjunctive treatment with statins in patients with hypertriglyceridemia. Icosapent ethyl is currently undergoing clinical trials to determine its anti-inflammatory effects in patients with coronavirus disease 2019 (COVID-19). This report describes 3 intensive care unit (ICU) patients with moderate to severe COVID-19 pneumonia treated with icosapent ethyl as part of their supportive care who had favorable outcomes. CASE REPORT Case 1 was a 75-year-old man with a past medical history of hyperlipidemia, hypertension, type 2 diabetes mellitus, obesity, and benign prostatic hyperplasia. Case 2 was a 23-year old man with a past medical history of type 2 diabetes mellitus and obesity. Case 3 was a 24-year old man with a history of autism. All cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection were confirmed from a nasopharyngeal swab using the Becton Dickinson nasopharyngeal reverse-transcription polymerase chain reaction. All patients in these cases were treated with a course of 2 g of icosapent ethyl twice a day by nasogastric tube. CONCLUSIONS This report of 3 cases describes the use of icosapent ethyl as a component of supportive treatments in ICU patients with moderate to severe COVID-19 pneumonia. However, as of yet there are no evidence-based treatments for SARS-CoV-2 infection from controlled clinical trials. The outcomes of ongoing clinical trials are awaited to determine whether icosapent ethyl has anti-inflammatory effects in patients with SARS-CoV-2 infection and which patients might benefit from the use of this adjunctive treatment.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Eicosapentaenoic Acid / COVID-19 Drug Treatment Type of study: Case report / Experimental Studies / Prognostic study Limits: Adult / Aged / Humans / Male / Young adult Language: English Journal: Am J Case Rep Year: 2020 Document Type: Article Affiliation country: AJCR.928422

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Eicosapentaenoic Acid / COVID-19 Drug Treatment Type of study: Case report / Experimental Studies / Prognostic study Limits: Adult / Aged / Humans / Male / Young adult Language: English Journal: Am J Case Rep Year: 2020 Document Type: Article Affiliation country: AJCR.928422